1. Home
  2. IPHA vs NRO Comparison

IPHA vs NRO Comparison

Compare IPHA & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.49

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Logo Neuberger Berman Real Estate Securities Income Fund Inc.

NRO

Neuberger Berman Real Estate Securities Income Fund Inc.

HOLD

Current Price

$2.55

Market Cap

186.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IPHA
NRO
Founded
1999
N/A
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
165.3M
186.3M
IPO Year
2014
2003

Fundamental Metrics

Financial Performance
Metric
IPHA
NRO
Price
$1.49
$2.55
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $6.67
N/A
AVG Volume (30 Days)
33.5K
★ 222.3K
Earning Date
09-17-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$390.56
N/A
Revenue Next Year
$143.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.17
$2.48
52 Week High
$2.71
$3.23

Technical Indicators

Market Signals
Indicator
IPHA
NRO
Relative Strength Index (RSI) 41.16 40.70
Support Level $1.36 $2.49
Resistance Level $1.57 $2.61
Average True Range (ATR) 0.08 0.04
MACD 0.02 0.01
Stochastic Oscillator 33.33 46.19

Price Performance

Historical Comparison
IPHA
NRO

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

About NRO Neuberger Berman Real Estate Securities Income Fund Inc.

NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").

Share on Social Networks: